Anupam Rasayan India Ltd — earnings calls

Anupam Rasayan reported its highest ever annual revenue for FY26, with consolidated revenue from operations at INR2,384 crores, up 65% year-on-year, and EBITDA margin of 23%. The company completed the acquisition of Jayhawk Fine Chemicals and announced a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma along with an open offer for up to 26% additional shares. Management described diversification away from agrochemicals, with pharma revenue growing to INR339 crores in FY26 from INR21 crores in FY22, and outlined plans to integrate Tanfac, Jayhawk and Bliss GVS Pharma into its platform strategy.